You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 299 No. 7, February 20, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (2)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Bacterial Infections
 •Ophthalmology
 •Pediatric Ophthalmology
 •Ophthalmological Disorders, Other
 •Pediatrics
 •Pediatrics, Other
 •World Health
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Comparison of Annual and Biannual Mass Antibiotic Administration for Elimination of Infectious Trachoma

Muluken Melese, MD, MPH; Wondu Alemayehu, MD, MPH; Takele Lakew, MD, MPH; Elizabeth Yi, MPH; Jenafir House, MPH, MSW; Jaya D. Chidambaram, MBBS; Zhaoxia Zhou, BA; Vicky Cevallos, MT; Kathryn Ray, MA; Kevin Cyrus Hong, BA; Travis C. Porco, PhD, MPH; Isabella Phan, MD; Ali Zaidi, MD; Bruce D. Gaynor, MD; John P. Whitcher, MD, MPH; Thomas M. Lietman, MD

JAMA. 2008;299(7):778-784.

Context  Treatment recommendations assume that repeated mass antibiotic distributions can control, but not eradicate or even locally eliminate, the ocular strains of chlamydia that cause trachoma. Elimination may be an important end point because of concern that infection will return to communities that have lost immunity to chlamydia after antibiotics are discontinued.

Objective  To determine whether biannual treatment can eliminate ocular chlamydial infection from preschool children and to compare results with the World Health Organization–recommended annual treatment.

Design, Setting, and Participants  A cluster-randomized clinical trial of biannual vs annual mass azithromycin administrations to all residents of 16 rural villages in the Gurage Zone, Ethiopia, from March 2003 to April 2005.

Interventions  At scheduled treatments, all individuals aged 1 year or older were offered a single dose of oral azithromycin either annually or biannually.

Main Outcome Measure  Village prevalence of ocular chlamydial infection and presence of elimination at 24 months in preschool children determined by polymerase chain reaction, correcting for baseline prevalence. Antibiotic treatments were performed after sample collections.

Results  Overall, 14 897 of 16 403 eligible individuals (90.8%) received their scheduled treatment. In the villages in which residents were treated annually, the prevalence of infection in preschool children was reduced from a mean of 42.6% (range, 14.7%-56.4%) to 6.8% (range, 0.0%-22.0%) at 24 months. In the villages in which residents were treated biannually, infection was reduced from 31.6% pretreatment (range, 6.1%-48.6%) to 0.9% (range, 0.0%-4.8%) at 24 months. Biannual treatment was associated with a lower prevalence at 24 months (P = .03, adjusting for baseline prevalence). At 24 months, no infection could be identified in 6 of 8 of those treated biannually and in 1 of 8 of those treated annually (P = .049, adjusting for baseline prevalence).

Conclusion  Local elimination of ocular chlamydial infection appears feasible even in the most severely affected areas, although it may require biannual mass antibiotic distributions at a high coverage level.

Trial Registration  clinicaltrials.gov Identifier: NCT00221364


Author Affiliations: Orbis International, Addis Ababa, Ethiopia (Drs Melese, Alemayehu, and Lakew) and FI Proctor Foundation (Drs Lakew, Porco, Phan, Zaidi, Gaynor, Whitcher, and Lietman, Mss Yi, House, Chidambaram, Zhou, Cevallos, and Ray, and Mr Hong), Departments of Ophthalmology (Drs Phan, Gaynor, Whitcher, and Lietman) and Epidemiology and Biostatistics (Drs Porco, Whitcher, and Lietman), and Institute for Global Health (Drs Whitcher and Lietman), University of California, San Francisco.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

RELATED ARTICLES

Frequency of Antibiotic Coverage and Elimination of Blinding Trachoma
Alfred Sommer
Arch Ophthalmol. 2008;126(7):1000-1001.
EXTRACT | FULL TEXT  

Mass Antibiotic Administration for Eradication of Ocular Chlamydia trachomatis
David Mabey and Anthony W. Solomon
JAMA. 2008;299(7):819-821.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Eliminating Trachoma
JWatch Infect. Diseases 2008;2008:4-4.
FULL TEXT  

All you need to read in the other general journals
BMJ 2008;336:472-473.
FULL TEXT  

Mass Antibiotic Administration for Eradication of Ocular Chlamydia trachomatis
Mabey and Solomon
JAMA 2008;299:819-821.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.